A real-world retrospective cohort study investigated factors influencing weight loss response to subcutaneous GLP-1 analogs (86% of patients were prescribed subcutaneous SMG, and 14% were prescribed liraglutide) in 483 adults with obesity (BMI ≥30 kg/m2) at a multidisciplinary clinic in Vancouver, Canada (2018–2021). The gene discussed is GLP1R; the disease is obesity disorder.